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2316Objective: The aim of the present study was to construct a new drug delivery system for milrinone using mi-
croparticles. This novel technology enhances drug bioavailability and decreases toxicity, with future implica-
tions for the treatment of end-stage heart failure.
Methods: Polylactic-co-glycolic acid microparticles (PLGA-MPs) loaded with milrinonewere prepared using a
double emulsion-solvent evaporation technique. In vitro release kinetics was evaluated at physiologic condi-
tions. A total of 24 female Lewis rats underwent left coronary artery ligation. One week after ligation, all
rats were randomized to 1 of 3 groups (n ¼ 8 per group). Group I received an intravenous injection of
PLGA-MPs alone; group II, a bolus intravenous injection of milrinone; and group III an intravenous injection
of milrinone-PLGA-MPs. All injections were administrated slowly by way of the tail vein over 10 minutes.
Transthoracic echocardiography, noninvasive heart rate monitoring, and blood pressure measurements were per-
formed at different predetermined intervals before and for 24 hours after the injection. All rats survived for 24
hours and were then killed by euthanasia. Serum plasma was taken for cytokine assays and determination of
milrinone levels using high-performance liquid chromatography.
Results: Group III had a significantly greater left ventricular ejection fraction at 90 minutes and 3, 6, and
12 hours after treatment compared with the other groups. The milrinone plasma level was significantly
greater in group III than in the other groups (group I, 0 ng/mL; group II, 1.7  2.4 ng/mL; group III, 9.1 
2.2 ng/mL; P<.05). The intercellular adhesion molecule and cytokine-induced neutrophil chemoattractant-1
levels were significantly lower in group III than in the other 2 groups (P<.05).
Conclusions: Drug encapsulation using microparticles can prolong the effects of milrinone. We propose a
new strategy for future drug delivery in patients with end-stage heart failure. (J Thorac Cardiovasc Surg
2014;148:2316-24)Nanomedicine is a new multidisciplinary field that has
demonstrated promising potential in medical therapeutic
and diagnostic applications. This evolving field includes
micro- and nanoparticles (MNPs) whose structures exhibit
distinct physical, chemical, and biologic properties owing
to their small size. These features make them highly valu-
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systems.1 Drug encapsulation using MNPs could have the
advantages of increasing the drug circulation time and pass-
ing across biologic barriers to allow subsequent internaliza-
tion and distribution within tissues of interest through
passive and active targeting mechanisms.2
Milrinone is a type III phosphodiesterase inhibitor that
has strong inotropic and vasodilator effects. It has little ef-
fect on the heart rate and oxygen consumption, offering an
advantage over other cardiac inotropes.3Milrinone has been
commonly used to treat low cardiac output and high pulmo-
nary arterial pressure.4 It also exhibits an anti-inflammatory
effect, such that its role in the management of systemic
inflammatory response syndrome after cardiopulmonary
bypass5 and/or sepsis has become more apparent.6,7 The
half-life of milrinone in humans is approximately 2 hours;
thus, it is usually given by way of a central line as a contin-
uous infusion in a monitored setting.8 Intravenous milri-
none has been reported to have been given as an
outpatient therapy for patients with end-stage heart failure
who required frequent repeat hospitalizations, were
inotropic dependent, or were awaiting either heart trans-
plantation or implantation of a ventricular assist device.9,10
The logistics of outpatient, intravenous administration of agery c November 2014
Abbreviations and Acronyms
CINC-1 ¼ cytokine-induced neutrophil
chemoattractant-1
DDQ ¼ 2,3 dichloro-5,6-dicyanobenzoquinone
HPLC ¼ high-performance liquid
chromatography
ICAM-1 ¼ intercellular adhesion molecule-1
IL-10 ¼ interleukin 10
LVEF ¼ left ventricular ejection fraction
LVFS ¼ left ventricular fractional shortening
MNPs ¼ micro- and nanoparticles
MPs ¼ microparticles
PLGA ¼ polylactic-co-glycolic acid
TNF-a ¼ tumor necrosis factor-a
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Spotent inotrope requires tremendous paramedical support
and is costly and potentially hazardous. The oral form of
milrinone is less effective with less predictable outcomes,
such that it is rarely used clinically.11
The objective of the present study was to construct a new
drug delivery system for milrinone using biodegradable mi-
croparticles (MPs) to enhance drug bioavailability with
controlled pharmacokinetics and to decrease the cytotox-
icity and dosage frequency. This could potentially offer a
novel therapeutic strategy, similar to insulin administration
for patients with diabetes, for the treatment of patients with
end-stage heart failure. We hypothesized that intravenous
injection of milrinone prepared in biodegradableMPsmight
prolong its inotropic effect by sustained a slow-release
mechanism that enhances myocardial function in a rat
model of ischemic cardiomyopathy. To the best of our
knowledge, this is the first study that delivered cardiac ino-
tropes using biodegradable MP technology.E
T
/METHODS
In Vitro Studies
MP preparation. Biodegradable polylactic-co-glycolic acid
(PLGA)-MPs were loaded with milrinone using a double emulsion-
solvent evaporation technique. In brief, milrinone solution (2.5 mg) was
added to PLGA (50 mg) dissolved in 1 mL dichloromethane. The primary
emulsion was generated by a high-speed homogenizer (PowerGen 125;
Thermo Fisher Scientific, Waltham, Mass) for 2 minutes. Double emulsion
was achieved by adding the emulsion to 10 mL of 0.5% (wt/vol) polyvinyl
alcohol and homogenizing again for another 1 minute. To remove the
organic solvent, the resultant water-in-oil-in-water emulsion was placed
under magnetic stirring for 3 hours at room temperature. After 3 hours,
the hardened PLGA-MPs were then washed 3 times with distilled water
by centrifugation. TheMPs were prepared in 3 different batches and frozen
at 20C for future use.
Morphology and Structure Characterization of
Microspheres
The morphology of the microspheres was studied using scanning elec-
tron microscopy (Hitachi S-4700 FE; Hitachi, Chiyoda, Japan). The sizeThe Journal of Thoracic and Carwas confirmed using a particle sizer instrument. The diameter of the
MPs was measured using the technique of electrophoretic laser Doppler
anemometry and a Zeta Potential Analyzer (Brookhaven Instruments
Corp, Holtsville, NY). The ZetaPlus Particle Sizer software, version 4.11
(Brookhaven Instruments Corp) was used to determine the size distribution
of the MPs. The particle sizes were measured for 3 batches of MPs, and
each measurement was obtained after taking the average of the 3 runs.
Milrinone Encapsulation Efficiency and Release
Kinetics
The percentage of encapsulated milrinone drug was estimated using the
2,3 dichloro-5,6-dicyanobenzoquinone (DDQ) test as described previ-
ously.12 In brief, DDQwas used as a oxidative coupling and charge transfer
reagent to quantify the milrinone concentration using a spectrophotometer.
The drug loading efficiency was determined by dissolving accurately
weighed amounts of drug-carrying MPs (approximately 15 mg) in 5 mL
acetonitrile and subsequent quantification by adding the DDQ solution
(0.05% wt/vol) in methanol and reading the absorbance at 356 nm. To
detect the release kinetics, the drug-loaded MPs were placed in 10 mL
phosphate-buffered saline and into glass vials. The containers were hori-
zontally shaken at 37C. At predetermined intervals, 1-mL samples were
withdrawn (replaced with fresh phosphate-buffered saline) and treated
with DDQ for quantification using spectrophotometry. Each experiment
was conducted in triplicate.In Vivo Studies
All experiments were performed on female Lewis rats (weight,
200-250 g; Charles River Laboratories, Wilmington, Mass) in accordance
with the guidelines set forth by the Canadian Council on Animal Care and
were approved by the institutional ethics committee.
Ligation of Left Anterior Descending Coronary
Artery and Intravenous MP Injection
Ligation of the left anterior descending artery was performed through a
left thoracotomy, as previously described.13 One week after ligation, all 24
rats were randomized into 1 of 3 groups. Group I received intravenous tail
vein injection of empty PLGA-MPs (250 mL). Group II received a bolus
intravenous tail vein injection of milrinone (50 mg/kg in 250 mL) slowly
over 10 minutes.14,15 Finally, group III received an intravenous tail vein
injection of milrinone prepared in PLGA-MPs in an equivalent dose and
volume as in group II. The reason for using empty MPs as a control was
to ensure that these particles per se had no effect on cardiac function or
other inadvertent toxicity. Various endpoint measurements were taken as
described in subsequent paragraphs. At 24 hours after tail vein injection,
all rats were killed by euthanasia. The hearts were washed with
phosphate-buffered saline solution to remove excess blood and clots and
then fixed in neutral-buffered 4% formalin. Blood was collected and
centrifuged at 1200 rpm for 20 minutes, and the serum plasma was stored
at 80C for additional analysis.
Echocardiography, Heart Rate, and Blood Pressure
Measurements
Echocardiographic examinations and heart rate and blood pressure mea-
surements were performed with the rats under inhaled isoflurane anesthesia
(2.5% in oxygen, 500-700 mL/min). Baseline transthoracic echocardiogra-
phy was performed on day 4 after left anterior descending artery ligation for
each rat, followed by serial measurements, after tail vein injection, at the
following intervals: 30 and 90 minutes, and 3, 6, 12, and 24 hours. Serial
echocardiograms were performed in a blinded fashion using a commercially
available system (Micromaxx P04224; SonoSite, Bothell, Wash), equipped
with a linear probe, 7 to 13-MHz, 25-mm footprint, turbo transducer
(P06519.11; SonoSite). The left ventricular end-diastolic and end-systolicdiovascular Surgery c Volume 148, Number 5 2317
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posterior walls from the parasternal short-axis view just below the level
of the papillary muscles. The time of end diastole was defined as the time
of the maximum diameter of the left ventricle in 1 heart cycle. Accordingly,
end systole was defined as the minimum diameter. The left ventricular frac-
tional shortening (LVFS) and left ventricular ejection fraction (LVEF) were
estimated using the American Society of Echocardiography leading-edge
method, as previously described.16
The mean arterial blood pressure and heart rate measurements were ob-
tained using the CODA standard noninvasive blood pressure system (Kent
Scientific Corp, Torrington, Conn). The measurements were done serially
after intravenous tail injection at 5, 15, 30, and 90 minutes.
Cytokine Measurement
To determine the pro-inflammatory/anti-inflammatory cytokine ratio,
we measured the plasma level of tumor necrosis factor (TNF)-a and inter-
leukin (IL)-10 using enzyme-linked immunosorbent assay kits (Biosource,
Invitrogen, Life Technologies, Norwalk, Conn) according to the manufac-
turer’s recommendations. In addition, the relative cytokine level was de-
tected in rat plasma using the Proteome Profiler Rat Cytokine Array
Panel A (R&DSystems,Minneapolis, Minn), as instructed by the manufac-
turer. The average signal (pixel density) of the pair of duplicate spots rep-
resenting each cytokine was determined and subtracted from the
background according to the manufacturer’s recommendations.17
Measurement of Milrinone Level Using High-
Performance Liquid Chromatography
Materials. Milrinone lactate, a 1-mg/mL solution for injection, was
prepared (Sandoz Canada Inc, Boucherville, Quebec, Canada). Amrinone
was used as an internal standard and was obtained from Sigma-Aldrich
(Oakville, Ontario, Canada). High-performance liquid chromatography
(HPLC)-grade methanol, HPLC-grade acetonitrile, phosphoric acid, and
dipotassium phosphate were obtained from Fisher Scientific Inc (Ottawa,
Ontario, Canada). Water was purified on site by reverse osmosis and
Milli-Q (Millipore Corp, Billerica, Mass).
Chromatography. The HPLC system included the Beckman System
Gold 126 binary pump, Beckman System Gold 166 variable wavelength
detector, Beckman System Gold 508 autosampler and Flatron TC-50 col-
umn thermostat. The chromatographic data were collected and processed
using 32 Karat software (Beckman Coulter Canada Inc, Mississauga,
Ontario, Canada). The separation of milrinone lactate and amrinone was
achieved using the Symmetry C18, 5 mm, 4.73 150 mm, column (Waters,
Milford, Mass). The mobile phase composition was 37.5% methanol and
62.5% 5 mM K2HPO4 buffer in Milli-Q water and was adjusted to pH
7.4 with H3PO4. The mobile phase was filtered on a Teflon 0.45-mm filter
and degassed before the use. It was used as an isocratic elution with the flow
rate of 1.4 mL/min. Internal standard solution was prepared by dissolving
1.0 mg of amrinone in 500 mL HPLC-grade acetonitrile. The amrinone
solution had 2 functions—to introduce the internal standard into the sample
and to precipitate plasma proteins. The standard solution of milrinone
lactate was prepared by dilution of 1 mg/mL original milrinone lactate
solution in Milli-Q water. A 200 mL plasma aliquot was transferred into
a 1.5-mL polypropylene microcentrifuge tube and 800 mL of amrinone
solution was added before the tube was closed, vortexed at high speed
for 1 minute, and centrifuged at 12,000 g for 3 minutes. After centrifuga-
tion, the supernatant was transferred into a clean glass test tube (10 3 75
mm) and evaporated at 60C under a gentle flow of dry nitrogen. After
complete liquid evaporation, 100 mL of the mobile phase was added to
the test tube and vortexed for 30 seconds. Next, the liquid was transferred
into an HPLC vial with 100 to 150 mL for analysis. The injection volume
was 27 mL. Standard samples were prepared exactly the same way,
with the only difference that, instead of plasma, the standard solution of
milrinone lactate with a concentration of 1 to 1000 ng/mL was used.2318 The Journal of Thoracic and Cardiovascular SurMethod Validation
The recovery of milrinone was estimated as 84%, acceptable for the in-
ternal standard method. The detection limit was 2.5 ng/mL and the quanti-
tation limit was 5 ng/mL. The method is linear in the wide concentration
range (5-1000 ng/mL), with the least squares weighting 1/response^ 2.
The goodness of fit (r^ 2) was 0.997.
Statistical Analysis
All statistical analyses were performed using the Statistical Package for
Social Sciences program, version 16 (SPSS, Chicago, Ill). All statistical
tests were 2-tailed. All data are presented as the mean standard deviation.
Repeated echocardiographic variables, heart rate, and blood pressure mea-
surements were compared using 1-way repeated measures analysis of vari-
ance. In addition, analysis of variance was used to compare the cytokine
and milrinone level among the groups at 24 hours after injection. If a sig-
nificant F-ratio were obtained, a Bonferroni post hoc test was used to assess
the pair-wise differences.
RESULTS
Morphology and Structure Characterization of
Microspheres
Electron microscopic analysis confirmed the presence of
MPs and provided morphologic information on typical
milrinone-loaded PLGA-MPs (Figure 1, A). The particles
were about 4 to 5 mm in diameter. They had an oval shape
and smooth surfaces. Loading the PLGA-MPs with milri-
none did not result in any significant change in the shape
or size of the MPs.
Milrinone Encapsulation Efficiency and Release
Kinetics
The encapsulation efficiency of milrinone with different
PLGA concentrations is shown in Figure 1, B. At a milri-
none/PLGA concentration ratio of 1:10 and 1:20, the encap-
sulation efficiency was 16.45%  4.3% and 23.62% 
3.3%, respectively. No significant change was found in
the size compared with the free MPs. Increasing the milri-
none/PLGA concentration ratio to 1:40 resulted in improve-
ment in the encapsulation efficiency to 27.96%  5.6%,
with an increase in the MP size to 7.38  5.6.
The percentage of milrinone release from the PLGA par-
ticles within 24 hours is illustrated in Figure 1, C. An initial
burst effect release phase occurred, followed by a lag
release phase, characteristic of PLGA-MPs.18,19 Changing
the milrinone/PLGA ratio from 1:10 to 1:40 decreased the
amount of milrinone released during the burst and lag
phases. A milrinone/PLGA ratio of 1:20 was selected for
the in vivo experiments because the encapsulation of
milrinone at this concentration resulted in minor changes
in the MP size and shape, with gradual and slow release
of milrinone over 24 hours.
Echocardiography, Heart Rate, and Blood Pressure
Measurements
Figure 2, A and B, show the mean standard deviation of
the LVEF and percentage of LVFS measured for all thegery c November 2014
FIGURE 1. Characterization of microparticles. A, Transmission electron microscopy was used to obtain the size characterization. The polylactic-co-
glycolic acid (PLGA) microparticles (MPs) measuredz4 mm in diameter. Most microparticles were spherical in shape. B, Encapsulation efficiency using
various milrinone (Mil)-PLGA concentrations. C, In vitro release kinetics of milrinone (Mil)-loaded PLGA microparticles over time. Mil-PLGA
concentration of 1:20 was used in this study.
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at baseline and after left anterior descending artery ligation
were not significantly different among the groups (P>.05).
At 30 minutes, the mean LVEF and LVFS measured in
group III (LVEF, 73%  9%; LVFS, 52%  6%) and
group II (LVEF, 69%  3%; LVFS, 44%  3%) were
significantly greater than those in group I (LVEF, 47% 
2%; LVFS, 26%  0.6%; P< .05). At 90 minutes, the
mean LVEF and LVFS in group III (LVEF, 72%  8%;
LVFS, 51%  6%) were significantly greater than those
in both group I (LVEF, 46%  3%; LVFS, 25%  1%)
and group II (LVEF, 60%  7%; LVFS, 36%  5%;
P < .05). At 3, 6, and 12 hours, the mean LVEF and
LVFS in group III had gradually decreased but were never-
theless significantly greater than in the other groupsThe Journal of Thoracic and Car(P< .05). At 24 hours, group III had a tendency toward
greater LVEF and LVFS recovery after injection compared
with that in groups I and II, but the difference did not reach
statistical significance (P>.05). Figure 2, C and D, shows
the mean and standard deviations of the mean arterial blood
pressure and heart rate in all groups. One-way analysis of
variance showed no significant differences among the
groups at the predetermined intervals (P>.05).
Serum Cytokine Measurements
The mean pro-inflammatory/anti-inflammatory cytokine
ratio (TNF-a/IL-10) measured in the plasma of all rats is
shown in Figure 3, A. The serum TNF-a/IL10 ratio was
significantly greater in group I (6.2  1.1) than in groups
II and III (4.2  0.4 and 3.8  0.8, respectively, P<.05).diovascular Surgery c Volume 148, Number 5 2319
FIGURE 2. Hemodynamic measurements. Data presented as mean  standard deviation. A, Graphs of left ventricular ejection fraction determined by 2-
dimensional images. B, Graphs of percentage of fractional shortening determined by 2-dimensional images. C, Graphs of mean arterial pressure measure-
ments. D, Graphs of heart rate measurements. *P<.05, group III versus groups I and II; cP<.05, group III versus group I; **P<.05 group II versus group I.
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the difference did not reach statistical significance (P>.05).
The relative multicytokine panel is shown in Figure 3, B.
Vascular endothelial growth factor and macrophage inflam-
matory protein-3a signals were absent in groups II and III.
The relative pixel density of cytokine-induced neutrophil
chemoattractant-1 (CINC-1) and intercellular adhesion
molecule-1 (ICAM-1) in group III (CINC-1, 0.86  0.02;
ICAM-1, 0.18  0.01) were significantly lower than those
in group I (CINC-1, 1.03  0.02; ICAM-1, 1.01  0.04)
and group II (CINC-1, 0.98  0.04; ICAM-1, 0.31 
0.01; P<.05).
Milrinone Assay Using HPLC
Both milrinone lactate and amrinone were detected at a
wavelength of 325 nm. The retention time of milrinone
was 6.15 minutes and of amrinone (internal standard) was
3.93 minutes. The total run time was 8 minutes. HPLC anal-
ysis (Figure 4) showed that the milrinone plasma level at 24
hours after treatment in group III was significantly greater
than that in groups I and II (group I, 0 ng/mL; group II,
1.7  2.4 ng/mL; group III, 9.1  2.2 ng/mL; P<.05).
DISCUSSION
The technologies of MNPs have advanced tremendously
during the past 2 decades for their potential applications in2320 The Journal of Thoracic and Cardiovascular Survarious healthcare fields. MNPs promote the innovative cre-
ation of drug delivery systems that increase drug bioavail-
ability, decrease toxicity, and enhance drug targeting by
passive or active mechanisms.20 The US Food and Drug
Administration has approved several drug delivery systems
using these particles. Most of these drugs were used in the
field of oncology, such as polyethylene glycol-stabilized
liposomal doxorubicin (Doxil, Evacet), protein-bound
paclitaxel (Abraxane), and pemetrexid (Alimta) to deliver
a highly toxic drug in a target-specific site with minimal
side effects.21 In cardiovascular drug delivery, MNPs have
been used in different settings that focused mainly on the
treatment of in-stent restenosis.22,23 In the present study,
we have demonstrated the feasibility of using MPs to
prolong the inotropic effect of a single injection of
milrinone by a slow drug release mechanism attributed to
the semipermeable properties of the polymer. To our
knowledge, this is the first report to use MPs to deliver
cardioactive drugs for the treatment of heart failure.
TheMPs used in the present study for milrinone encapsu-
lation were prepared from PLGA polymer, one of the most
widely used Food and Drug Administration-approved
biodegradable polymers. This polymer has the following
attractive features: biocompatibility, well-described formu-
lations and methods of preparation adapted to various types
of hydrophilic (eg, milrinone) or hydrophobic druggery c November 2014
FIGURE 3. Plasma cytokine levels for group I (empty microparticles), group II (milrinone), and group III (microparticles plus milrinone). A, Ratio of
serum tumor necrosis factor (TNF)-a to interleukin-10 levels. *P<.05, group I versus groups II and III. B, Rat cytokine panel. A, upper, Representative
array images shown. Lower, Profiles, created by quantifying dot densities, background-subtracted, and normalized to positive controls, are presented. Note
the signal intensities of serum intercellular adhesion molecule (ICAM) and cytokine-induced neutrophil chemoattractant-1 (CINC-1) in group III were
significantly less than in the other groups. Macrophage inflammatory protein-3a (MIP-3a) and vascular endothelial growth factor (VEGF) were absent
in groups II and III. *P< .05, group III versus groups I and II; **P< .05, group II versus group I; cP< .05, group I versus groups II and III. LIX,
Lipopolysaccharide-induced CXC chemokine; RANTES, chemokine ligand-5; TIMP-1, tissue inhibitors of metalloproteinase-1; IL-10, interleukin 10.
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tion, and protection of drugs from rapid degradation.24
The size of the PLGA-MPs used in the present study was
about 4 mm, ideal for the intravenous route and providing
sustained systemic release of the drug without the risk of
embolization. Particles>10 mmwill persist at the site of in-
jection and would be appropriate for local delivery25; how-
ever, particles<1 mm will be ideal for targeted therapy
because of their ability to cross the mucous barrier, endothe-
lial cells, and even the blood-brain barrier.26 The release ki-
netics curve of milrinone in vitro showed an initial burst
effect, characteristic of the PLGA MPs. The initial burst
release is the quantity of the drug that escapes from the
MPs before the onset of polymer erosion-mediated drug
release.27 We found that the burst effect in vitro was at 6
to 7 hours; however, the increase in the LVEF after injecting
milrinone-PLGA-MPs in the rat was early, within the first
30 minutes. This discrepancy could have been because mil-
rinone is a hydrophilic drug, which will facilitate its diffu-
sion to the surface of the particles, especially after
entering the blood stream.28 The fast burst effect could be
modified by wide particle size distributions or coating theThe Journal of Thoracic and CarMPs with materials that can provide a protective layer to
help in delaying the burst effect and increasing the circula-
tion time.29 As such, manyMNP-designed options are tech-
nically available to obtain the optimal pharmacokinetics
desirable for drugs for different clinical purposes.
Milrinone has been widely used clinically in the treat-
ment of low cardiac output, pulmonary hypertension, and
right ventricular failure. It has a class IIb indication for
continuous long-term support for patients with end-stage
heart failure who are inotropic dependent and awaiting
either transplantation or ventricular assist device implanta-
tion.30 In the present study, we have shown a significant re-
covery in left ventricular contractility in the group receiving
milrinone-PLGA-MPs compared with the other groups for
12 hours or, potentially, 24 hours. The effect was pro-
longed 4 times longer than milrinone as a free drug given
at the same dose and using the same route. No significant
differences were found in the heart rate or mean arterial
blood pressure among the groups. The milrinone dose
used in the present study was arbitrarily similar to that
used in the published data. Just as confirmed by Verrijk
and colleagues31 at the same dosage used in our study, thediovascular Surgery c Volume 148, Number 5 2321
FIGURE 4. High-performance liquid chromatography of milrinone in rat plasma. A, Group I (empty microparticles); B, group II (milrinone); and C, group
III (microparticles plus milrinone). D, The mean plasma milrinone level in all 3 groups at 24 hours after tail vein injection. SD, Standard deviation.
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the heart rate was mild. Apart from its strong inotropic ef-
fect, milrinone also has essential anti-inflammatory effects
that have been reported in many experimental and clinical
trials in the settings of myocardial infarction, congestive
heart failure, cardiopulmonary bypass, and sepsis. These ef-
fects are probably indirectly related to the improvement in
the hemodynamics after administering the drug. However,
direct effects by elevating cyclic adenosine monophosphate
and inhibiting the NF-kB pathway, which will decrease the
production of pro-inflammatory cytokines, have been sug-
gested.32,33 Similar to previous reports, we have shown
that giving a single dose of milrinone, either as a free
drug or prepared in MPs, could result in a significant
reduction of the pro-inflammatory markers (TNF-a, chemo-
kines CINC-1, macrophage inflammatory protein-3a,
ICAM, and vascular endothelial growth factor). In addition,
encapsulation of milrinone using MPs prolonged its effect
on the production of these cytokines, suggested by the
significantly lower level of CINC-1 and ICAM in group
III, despite group III having received the same dose of mil-
rinone as group II.
The present study had several limitations. First, this was
the first application of MNPs in the delivery of cardioactive
drugs. The dose–response characteristics, optimal hemody-
namic effects, and determination of unacceptable2322 The Journal of Thoracic and Cardiovascular Surhemodynamic side effects need to be defined. Nevertheless,
we have shown the feasibility of prolonging the inotropic
effect of milrinone without increasing the toxicity or side
effects. Second, no invasive hemodynamic monitoring
was used to obtain objective data regarding cardiac output,
blood pressure, heart rate, systemic resistance, pulmonary
pressure, and so forth. Transthoracic echocardiography
could potentially have created a bias, because it is operator
dependent. To minimize this bias, the echocardiographic
operator and analysis in the present study were blinded to
the type of injection and treatment. Third, no detailed
in vivo pharmacokinetics study was performed to document
milrinone release over time. Finally, the variation in
phosphodiesterase-3 expression across different species
should also be considered. This might have accounted for
the differences in inotropic effects on human versus rats.
It has been reported that more inotropic effect will be
seen at the same dose of milrinone in humans than in
rats.34 This reiterates the need for additional studies to
investigate the dose–response characteristics and species
differences with milrinone.
CONCLUSIONS
The encapsulation of milrinone in MPs could provide
new strategies for delivering these hemodynamically potent
drugs in a more gentle and prolonged fashion andgery c November 2014
Al Kindi et al Evolving Technology/Basic Scienceminimizing the hemodynamic side effects. Future studies
are needed to optimize the encapsulation and milrinone
release in a predictable manner. In addition, using PLGA-
MP technology could potentially develop different
sustained-release milrinone formulations, such as an intra-
muscular, a subcutaneous, or an oral form that can be deliv-
ered by various routes. Inhaled milrinone-PLGA-MPs is
one such example that sustained milrinone delivery can
be achieved by nasal administration with minimal systemic
side effects and toxicity. The application of MNPs in drug
delivery has proved to be effective and feasible. Additional
exploitation for cardiovascular application could hold great
potential for the treatment of patients with congestive heart
failure.E
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Dr Vivek Rao (Toronto, Ontario, Canada). Thank you. I have
no conflicts to disclose.
I would like to congratulate you on a very clear presentation and
a very interesting technological proof-of-concept study. You found
that the encapsulation of milrinone in these MPs led to a sustained
release of milrinone with potential beneficial effects.
I have 3 questions for you related to this study. The first is the
PLGA that you used for the MPs appears to me to be lipophilic.
In your in vitro release studies, you had phosphate-buffered saline.
Have you done studies in which you actually have a mono layer of
cells to determine whether the cells tend to accumulate this
particle?
Dr Al Kindi. PLGA polymer is hydrophobic, but it can
encapsulate the hydrophilic drugs by mechanical entrapment
inside its highly porous meshlike structure. That is the idea of
how this PLGA can release milrinone in a sustained way because
it is lipophilic, so the release will be slowly over 24 hours.
Dr Rao. But can be it absorbed into a cell wall and have..
Dr Al Kindi. Actually, the degradation of the PLGA in humans
is by hydrolysis. So, the end result is lactic acid, and the lactic acid
will be absorbed by the liver, and then that is how it is metabolized.
That is why it is biodegradable and approved by the Food and Drug
Administration.diovascular Surgery c Volume 148, Number 5 2323
Evolving Technology/Basic Science Al Kindi et al
E
T
/B
SDr Rao. My second question relates to the hemodynamic ef-
fects of both drug delivery systems. You mentioned that one of
the limitations was a lack of invasive hemodynamic assessments.
In the report, you documented that the heart rate and blood pres-
sure did not differ among the 3 groups.
How do you reconcile that intravenous injection of milrinone
did not cause tachycardia or a hypotensive effect, which is
commonly seen clinically?
Dr Al Kindi. That is an excellent question. The way we
measured the blood pressure and heart rate was a noninvasive
method using a tail cuff. It is noninvasive method and can be
affected by body temperature. We did not see any difference in
the heart rate and blood pressure among all 3 groups. Probably,
in future studies, we should measure the heart rate and blood pres-
sure more precisely, using invasive methods.
DrRao. Finally, in your conclusion, as well as in your last slide,
you tease us with the concept of using this alternative delivery
technique. So, do you have any preliminary data that you can share
with us in terms of prolonging the effect of milrinone therapy using
subcutaneous, intramuscular, or inhalational therapy?
Dr Al Kindi. Actually, the size of the MPs we used in this proj-
ect was 4 mm, which is ideal actually for the inhalation route.
That would also be a very good method to deliver milrinone and
to decrease its systemic side effects, so that is why we are thinking
along that line.
Dr David H. Harpole, Jr (Durham, NC). Excellent study, very
interesting. I wanted to have you give us a little of your insight. We
know that milrinone is truly an inotropic agent in the heart. It also,
as you mentioned in the very beginning, has vasodilatory effects in2324 The Journal of Thoracic and Cardiovascular Surthe pulmonary circulation, it unloads the right heart. Actually, a
number of investigators think that might be how it is more cardio-
protective, because it actually unloads the heart.
Now, your microspheres were large enough that they probably
would not be absorbed directly into the pulmonary circuit. You
just mentioned this. If you changed your delivery system to inhaled
with a slightly smaller particle, do you think youmight also receive
the benefit of the pulmonary unloading, which would help the right
heart in failure?
Dr Al Kindi. It all depends on your treatment target. If your
target is pulmonary hypertension, I think the inhalation method
would be appropriate in this context.
If you are treating heart failure or you want to have the systemic
effect of milrinone, perhaps the subcutaneous route or intramus-
cular route would be ideal. It all depends on your target.
Dr Todd K. Rosengart (Houston, Tex). It would appear that
what you are showing us is that you can extend the duration of
the effect from about 3 hours to 12 hours or so; however, perhaps
what is more exciting about this, as you alluded, is that nanopar-
ticles will allow the use of inhalation instead of the current
formulation.
So, is this a change in the method of delivery or is the impor-
tance of your study the duration of effect, or is it something else?
Dr Al Kindi. This study is the first study to use MPs to deliver
cardioactive drugs. So, we have to start with the intravenous route.
However, ultimately we are working on delivering these MPs us-
ing a more convenient method. As I mentioned, we will start
with the subcutaneous route and then to more difficult routes,
such as the inhalation route, and that is our ultimate goal.gery c November 2014
